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Dear Dr Fisher, 
We read with interest the recent controversies in stroke article “Embolic stroke, atrial 
fibrillation and microbleeds: is there a role for anticoagulation”1.  We congratulate the 
authors for highlighting the increasingly common and difficult clinical dilemma of 
anticoagulation in patients with cardioembolic stroke who are found to have cerebral 
microbleeeds (CMBs). They helpfully discuss some of the observational evidence, and 
articulate the persisting clinical uncertainty around this question. We agree with Dr 
Greenberg’s conclusion that holes in our knowledge need to be filled with hard data.  
A systematic review and meta-analysis of published prospective studies of 3067 patients with 
ischemic stroke or TIA found that CMBs were associated with a significant increased odds 
ratio for the risk of any recurrent stroke (OR, 2.25; 95% confidence interval [95% CI], 1.70-
2.98; P<0.0001). CMBs were associated with a higher odds ratio for the risk of intracerebral 
hemorrhage (OR, 8.52; 95%CI, 4.23-17.18; P=0.007) than ischemic stroke IS (OR, 1.55; 
95%CI, 1.12-2.13; P<0.0001). However, the vast majority of these patients were treated with 
antiplatelet agents: only a minority (less than 200) received anticoagulants. Thus, there is an 
urgent need for more data on whether CMBs influence the risk of ICH and IS in patients on 
anticoagulants to inform the debate. Importantly, both absolute and relative risks of ischemic 
stroke and intracerebral hemorrhage are needed; furthermore, how the burden and location of 
CMBs affects the magnitude and balance of risks also remains unknown.  
To address the many gaps in knowledge, observational studies are underway to specifically 
address the question of CMBs and stroke risk in individuals with cardioembolic (atrial 
fibrillation-associated) ischemic stroke treated by anticoagulation, including two large 
multicentre inception cohort studies:  Clinical Relevance of Microbleeds in Stroke (CROMIS 
2; see https://www.ucl.ac.uk/cromis-2, https://clinicaltrials.gov/ct2/show/NCT02513316)2 
and Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by 
Magnetic Resonance (HERO; see http://heropub.pic.es, 
https://clinicaltrials.gov/ct2/show/NCT02238470). The teams leading these studies (which 
have recruited over 2500 patients) have begun a collective systematic international individual 
patient data meta-analysis including individuals with presumed cardioembolic ischemic 
stroke related to atrial fibrillation, started for the first time on oral anticoagulation. Since 
intracranial haemorrhage (including intracerebral haemorrhage) is, thankfully, a rare 
consequence of oral anticoagulation, only such large-scale international collaborative efforts 
will provide useful and precise estimates of the risks associated with antithrombotic drugs in 
patients with CMBs. We warmly encourage other investigators to join in this international 
collaborative effort. Until data from such international efforts are available, clinicians will 
need to make individualised decisions, and we – to once again quote C Miller Fisher - will 
continue to “wake up once a week or so in a cold sweat” each time we anticoagulate a 
patient, especially if they have CMBs.  
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